Findings

What do systematic reviews say?

4 questions · 4 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 25%Moderate 3 · 75%High 0 · 0%

Cardiovascular mortality · patients with hypertension

CCBs may leads to lower cardiovascular mortality compared with β‐blocker (low certainty).

1 finding from 1 review

Calcium channel blockers versus other classes of drugs for hypertension 2022 · Cochrane Headline outcomes only
RR 0.9 [0.81, 0.99]
4 studies · 44825 participants
Low

Cardiovascular mortality · patients with hypertension

CCBs showed no clear difference in cardiovascular mortality compared with ACE inhibitor (moderate certainty).

1 finding from 1 review

Calcium channel blockers versus other classes of drugs for hypertension 2022 · Cochrane Headline outcomes only
RR 0.98 [0.89, 1.07]
6 studies · 27619 participants
Moderate

Cardiovascular mortality · patients with hypertension

CCBs showed no clear difference in cardiovascular mortality compared with ARB (moderate certainty).

1 finding from 1 review

Calcium channel blockers versus other classes of drugs for hypertension 2022 · Cochrane Headline outcomes only
RR 0.79 [0.54, 1.15]
3 studies · 4642 participants
Moderate

Cardiovascular mortality · patients with hypertension

CCBs showed no clear difference in cardiovascular mortality compared with diuretic (moderate certainty).

1 finding from 1 review

Calcium channel blockers versus other classes of drugs for hypertension 2022 · Cochrane Headline outcomes only
RR 1.02 [0.93, 1.12]
4 studies · 32721 participants
Moderate